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Summary
Intracerebroventricular administration of gut peptide PYY3–36 stimulates food intake. In contrast, peripheral administration
inhibits food intake, suggesting that the peptide has the opposite effect by virtue of accessing a unique subset of brain
sites. A previous study suggested that peripheral PYY3–36 activates anorexigenic POMC neurons in the arcuate nucleus,
and this was proposed to be the mechanism underlying the peptide’s anorexigenic activity. Here, we demonstrate in an
electrophysiological slice preparation that, in contrast to the original model, PYY3–36 potently and reversibly inhibits POMC
neurons via postsynaptic Y2 receptors. These data show a complex role for Y2 receptors in regulation of the NPY/POMC
circuitry, as they are present as inhibitory receptors on both the orexigenic NPY neurons as well as the anorexigenic
POMC neurons. Secondly, these data argue against a direct role of POMC neurons in mediating the anorexigenic response
to administration of peripheral PYY3–36.Introduction
Peptide YY (PYY) is synthesized by L cells of the lower gastro-
intestinal (GI) tract and released into the circulation after a meal
(Adrian et al., 1985; Pedersen-Bjergaard et al., 1996). In the
blood, the peptide is found in approximately equal concentra-
tions as the full-length (36 amino acid) and truncated (34 amino
acid) form, PYY3–36 (Grandt et al., 1994). The peptide has been
shown to have local effects on the GI system (Pappas et al.,
1985), such as inhibiting gut motility and gastric emptying, and
an orexigenic effect when administered centrally (Hagan, 2002;
Morley et al., 1985). However, peripheral administration of
PYY3–36 in pharmacological doses appears to have an anorexi-
genic effect (Adams et al., 2004; Batterham et al., 2002; Challis
et al., 2004; Chelikani et al., 2005; Cox and Randich, 2004;
Moran et al., 2005; Pittner et al., 2004).
The mechanisms underlying the anorexigenic action of
PYY3–36 have not been fully elucidated. In two studies, intrap-
eritoneal (i.p.) administration of PYY3–36 was found to activate
12%–13% of arcuate POMC neurons, as assayed by increase
in expression of c-fos (Batterham et al., 2002; Halatchev et al.,
2004). Bath application of PYY3–36 was observed to increase
action potential firing of POMC neurons in the arcuate nucleus
(ARC) in hypothalamic slices in vitro (Batterham et al., 2002).
Furthermore, another study has shown that PYY3–36 admin-
istration can slightly elevate proopiomelanocortin (POMC)
mRNA levels in hypothalamus (Challis et al., 2003). These
studies suggested that the anorexigenic effect of PYY3–36 is
mediated through activation of ARC POMC neurons (Batter-
ham et al., 2002). However, this model has been challenged by
more recent studies. First, inhibition of feeding by PYY3–36 was
demonstrated to persist in the melanocortin-4 receptor (MC4-R)
knockout mouse (Halatchev et al., 2004). Additionally, periph-
eral PYY is anorexigenic in the POMC knockout mouse3–36
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2004). Thus, release of melanocortin peptides derived from
POMC and their subsequent activation of the MC4-R, a well-
characterized anorexigenic pathway, does not appear to be re-
quired for the inhibition of feeding by PYY3–36. Several studies
now point to the brainstem as the primary central site of action
of peripherally administered PYY3–36 (Abbott et al., 2005; Ha-
latchev and Cone, 2005; Koda et al., 2005; Talsania et al.,
2005), in which case the modest activation of POMC neurons
reported may be secondary to activation of ascending brains-
tem projections. In order to elucidate the mechanisms underly-
ing the reduction of food intake by this peptide, we examined,
in more detail, the effects of PYY3–36 on POMC cells of the
arcuate nucleus in a hypothalamic slice preparation from the
mouse.
Results
PYY3–36 inhibits firing activity of POMC neurons
Action potential activities of POMC neurons recorded from hy-
pothalamic mouse slices were compared in saline and during
bath application of PYY3–36 using loose patch extracellular re-
cording. Results indicate that even nanomolar concentrations
of this peptide decrease the frequency of action potential firing
in POMC cells (Figure 1A). Results obtained from 12 POMC
cells on which 50 nM PYY3–36 was bath applied (Figure 1B)
indicate that this peptide significantly and reversibly decreased
their spontaneous firing frequency to 0.46 ± 0.27 Hz from 2.01 ±
0.42 Hz recorded in control conditions (w77% inhibition, n =
12, p < 0.0001). Furthermore, when 41 POMC cells were used
to investigate the effects of a wide range of PYY3–36 concentra-
tions, this peptide never elicited an excitatory response in
POMC cells; the inhibitory effect was dose dependent with
half-maximal inhibition around 7.5 nM (Figure 1C).ELSEVIER INC. DOI 10.1016/j.cmet.2005.08.003 191
S H O R T A R T I C L EFigure 1. PYY3–36 and NPY inhibit the spontaneous
firing of arcuate POMC neurons
A) Firing rate of a representative ARC POMC cell
measured with loose-patch recording is decreased
by bath application of PYY3–36 at 1, 25, and 100 nM
(indicated by the bars). The effect was reversible
and concentration dependent.
B) Average (±SEM) firing frequency of 12 POMC
neurons in saline and in 50 nM PYY3–36. *** indicates
p < 0.0001.
C) Inhibition of firing of 41 POMC neurons as a
function of the concentration of the bath applied
PYY3–36. The solid line shows the best fit through
the data point which indicates an IC50 = 7.5 nM
(R2 = 0.58).
D) Recording from a different representative ARC
POMC neuron showing the effects of 10, 1.0, and
100 nM NPY (indicated by the bars) on a spontane-
ously firing cell.
E) Average (±SEM) firing frequency of 27 POMC
neurons in saline and in 10–50 nM NPY. ***indicates
p < 0.0001.
F) The normalized inhibition of firing of 36 POMC
neurons as a function of the concentration of the
bath applied NPY. The solid line shows the best fit
through the data point which indicates an IC50 = 3.5
nM (R2 = 0.60).Previous studies have shown that NPY also inhibits action
potential firing in POMC cells of arcuate nucleus in mouse hy-
pothalamic slices via a postsynaptic Y1 receptor (Roseberry et
al., 2004). In order to compare the efficacy and potency of the
inhibitory effect of NPY with that of PYY3–36, we investigated
the effects of NPY on the firing activity of POMC neurons.
Using loose patch recordings, we compared the spontaneous
firing activity of POMC neurons in saline and during bath appli-
cation of NPY. Our data indicate that 10–50 nM NPY signifi-
cantly and reversibly reduced the firing frequency of the POMC
cells to 0.51 ± 0.12 Hz. from 3.38 ± 0.41 Hz in control (p <1920.0001, n = 20, Figures 1D and 1E). As reported (Roseberry et
al., 2004), this effect was found to be dose dependent with a
half-maximal inhibition around 3.5 nM (Figure 1F), near to that
of PYY3–36.
[ahx5–24]NPY, a selective Y2 agonist, inhibits firing
of POMC neurons
Previous studies in cells transfected with Y receptor subtypes
indicate that PYY3–36 has a higher affinity for Y2 versus Y1 re-
ceptors (Dumont et al., 1996; Keire et al., 2002). Furthermore,
expression of Y receptors on POMC cells of mouse hypothal-CELL METABOLISM : SEPTEMBER 2005
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PYY3–36 inhibits POMC neurons via postsynaptic Y2 receptorsamus has recently been suggested (Fetissov et al., 2004). We
therefore hypothesized that the selective Y2 agonist, [ahx5–24]
NPY, can mimic PYY3–36 in inhibiting the activity of these neu-
rons (Cabrele and Beck-Sickinger, 2000; El Bahh et al., 2002).
Therefore, the firing activity of 10 POMC cells, recorded using
loose patch method, were compared in saline and during appli-
cation of [ahx5–24]NPY (Figure 2A). The results (Figure 2B) indi-
cate that bath application of [ahx5–24]NPY, the selective Y2 ago-
nist, significantly decreased (p < 0.01) the frequency of firing
of these neurons (to 1.10 ± 0.46 Hz in 0.5–1.0 M [ahx5–24]NPY
from 2.80 ± 0.72 Hz in control conditions (n = 10).
Characterization of Y receptor subtypes
underlying the action of PYY3–36
Since [ahx5–24]NPY can inhibit the firing activity of POMC neu-
rons, we hypothesized that the inhibitory effect of PYY3–36 on
these cells is mediated through the activation of Y2 receptors.
We tested this hypothesis by comparing the inhibitory effect of
PYY3–36 on the spontaneous firing activity of 9 POMC cells in
the absence and presence of 500 to 1000 nM of BIIE0246, a
selective Y2 receptor antagonist (Doods et al., 1999). BIIE0246
strongly reduced the inhibitory effects of PYY3–36 on firing ac-
tivity in POMC cells, to 94.8 ± 6.5% of baseline values, versus
25.2 ± 7.1% in the presence of PYY3–36 alone (p < 0.005, n =
9) suggesting a role for Y2 receptors in mediating this effect
(Figures 2C and 2D).
Using cells transfected with Y receptors, a previous study
has shown that PYY3–36 can also bind to Y1 and Y5 receptors
with nanomolar affinity (Keire et al., 2002). We therefore tested
whether any component of the response of POMC neurons to
PYY3–36 might be mediated through either of these two recep-
tor subtypes. This hypothesis was tested by comparing the
inhibitory effect of PYY3–36 in the absence and presence of
BIBP3226 or L-152,802, blockers of Y1 and Y5 receptors re-
spectively (Kanatani et al., 2000; Rudolf et al., 1994). Our results
obtained from 14 POMC cells tested indicate that the re-
sponses of POMC cells to PYY3–36 was not significantly af-
fected in the presence of 0.5 to 1 M BIBP3226 (p > 0.5, n =
8, Figures 2E and 2F) or 1–2 M L-152,802 (p > 0.1, n = 6,
Figures 2G and 2H).
Characterization of Y receptor subtypes
underlying the action of NPY
The data described above identify a Y2-mediated response of
POMC neurons. However, an initial report suggested that NPY
inhibited firing of POMC neurons exclusively via the Y1 recep-
tor (Roseberry et al., 2004). Since NPY itself is a full agonist at
both Y1 and Y2 receptors (Keire et al., 2002; Sheikh et al.,
1989), the responses of POMC cells to NPY could actually be
mediated by either of these receptors. This hypothesis was
tested by comparing the response of POMC cells to bath-
applied NPY in the absence and presence of BIIE0246 or
BIBP3226, blockers of Y2 and Y1 receptors. On 7 neurons
tested, on which NPY alone reduced firing activity to 21.2 ±
5.7% of the baseline firing rate, application of BIIE0246 signifi-
cantly but incompletely diminished the inhibitory effect of NPY,
resulting in a reduction of firing rate to 42.5 ± 10.6% of baseline
values (p < 0.05, Figures 3A and 3B). Moreover, BIBP3226 also
significantly but partially blocked the inhibitory effects of NPY
in 6 other POMC cells tested, resulting in a reduction of firing
to 70.5 ± 13.5% of baseline values, compared to 32.9 ± 13.1%CELL METABOLISM : SEPTEMBER 2005in the presence of NPY alone (p < 0.05, Figures 3C and 3D).
Interestingly, as shown in Figures 2E and 3C, we observed that
application of BIBP3226 to naïve POMC neurons significantly
increased their action potential firing frequency from 2.5 ± 0.4
Hz in control to 3.9 ± 0.9 Hz (p < 0.05, n = 11). Although this
finding might suggest a blockade of endogenous activation of
Y1 receptor signaling by NPY released from cells in the slice, a
nonspecific effect of this compound on POMC cell activity can-
not be excluded.
We therefore decided to attempt to reproduce these results
using BIBO3304, a structurally different Y1 blocker (Wieland et
al., 1998). Our results indicate that, compared to reduction of
firing to 15.6 ± 2.5% of baseline levels with NPY alone, 1 M
BIBO3304 significantly but incompletely suppressed this inhi-
bition, resulting in a reduction of firing rate to 65.2 ± 5.5% of
baseline levels (p < 0.001, n = 9, Figures 3E and 3F). Moreover,
application of this more potent Y1 blocker alone significantly
increased the firing frequency of the all 9 POMC neurons
tested to 3.8 ± 0.9 Hz from 1.8 ± 0.7 Hz in control (p < 0.05),
in agreement with the observations made using BIBP3226.
Based on the above data, we hypothesized that both Y1 and
Y2 receptors contribute to the response of POMC neurons to
NPY, and tested this hypothesis by studying the response to
NPY in the presence of both BIIE0246 and BIBO3304. In six
POMC neurons, coapplication of BIIE0246 and BIBO3304 re-
duced the NPY-mediated inhibition of POMC neuron firing rate
almost entirely, from 8.5 ± 2.7% of baseline firing rate in the
presence of NPY alone to 94.7 ± 5.5% of baseline values in
the presence of both blockers. (p < 0.05, Figures 3G and 3H).
Are effects of PYY3–36 on ARC POMC neurons
mediated synaptically?
Blockade of GABAA and ionotropic glutamate receptors on
ARC POMC cells has been reported to abolish all spontaneous
synaptic events recorded from these neurons (Roseberry et al.,
2004). We therefore tested the hypothesis that the blockade of
receptors for these conventional neurotransmitters could alter
the PYY3–36-mediated inhibition of POMC neuron activity. To
examine this hypothesis we tested the effect of 25 to 50 nM
PYY3–36 on POMC neurons in the absence or presence of pic-
rotoxin (100 M), NBQX and AP5 (25 M each), to block GA-
BAA, and ionotropic glutamate synaptic transmission, respec-
tively. Our data indicate that application of these blockers did
not significantly affect firing frequency of POMC neurons (p >
0.1, n = 4). Furthermore, in the presence of these blockers the
inhibition of firing activity by PYY3–36 was not significantly dif-
ferent (p > 0.1, n = 4) from that seen in these cells in saline
(from 30.7 ± 16.4% in control to 22.6 ± 13.7%, Figures 4A
and 4B).
PYY3–36 hyperpolarizes POMC neurons
The data shown in Figures 4A and 4B suggest that PYY3–36
acts at a postsynaptic site on POMC cells to inhibit firing activ-
ity. We therefore hypothesized that PYY3–36 inhibits these cells
by directly hyperpolarizing the membrane potentials through
postsynaptic receptors. To test this, we examined changes in
membrane potential and the frequency action potential while
the POMC cells fired spontaneously at frequencies between
0.5 and 3 Hz. Application of 25–50 nM PYY3–36 significantly
and reversibly decreased the average firing frequency from
1.81 ± 0.55 Hz in control to 0.04± 0.01 Hz in 4 POMC cells193
S H O R T A R T I C L EFigure 2. The inhibitory effect of PYY3–36 is specifically mediated by the Y2 receptor
A) Firing activity of an ARC POMC cell showing consecutive applications of 50 nM PYY3–36 and 400 nM [ahx5–24]NPY (a Y2-preferring agonist, indicated by the bars).
Note that the [ahx5–24]NPY reversibly inhibited the firing activity and that the inhibition of firing activity exhibits little evident desensitization after multiple applications
of 50 nM PYY3–36.
B) Average (±SEM) firing frequency of 10 ARC POMC neurons in saline and in the presence of 0.5–1.0 M [ahx5–24]NPY. ** p < 0.01.
C) Effect of PYY3–36 on the firing activity of a POMC neuron in saline and in the presence of 0.9 M BIIE0246, a selective Y2 blocker (indicated by the bars). BIIE0246
significantly abolished the inhibitory effect of 50 nM PYY3–36 on neuronal firing.
D) Average (±SEM) of normalized inhibitory effect of PYY3–36 on nine POMC neurons in saline or in the presence of 0.5–1.0 M BIIE0246. ** indicates p < 0.005.
E) PYY3–36 inhibits POMC neuronal firing activity in saline or in the presence of 1 M BIBP3226, a Y1 specific antagonist (indicated by the bars). Note that BIBP3226
failed to block the inhibitory effect of 50 nM PYY3–36.
F) Average (±SEM) of normalized inhibitory effect of PYY3–36 on eight POMC neurons in saline or in the presence of 0.5–1.0 M BIBP3226. n.s., not significant; p > 0.5.
G) L-152,802 failed to significantly block the inhibitory effect of 50 nM PYY3–36 on POMC neuronal activity.
H) Average (±SEM) inhibitory effects of 10–50 nM PYY3–36 on firing activity of six POMC cells in saline or in the presence of 1–2 M of L-152,802. n.s., not significant;
p > 0.1.194 CELL METABOLISM : SEPTEMBER 2005
PYY3–36 inhibits POMC neurons via postsynaptic Y2 receptorsFigure 3. The inhibitory effect of NPY is mediated by the Y1 and Y2 receptors
A) Effect of NPY on firing activity of an ARC POMC neuron in saline and in the presence of BIIE0246 (indicated by the bars). BIIE0246 slightly but significantly reduced
the inhibitory effect of 20 nM NPY on POMC neuronal activity.
B) Average (±SEM) inhibitory effects of 20–50 nM NPY on firing activity of six POMC cells in saline and in the presence of 0.5–1 M BIIE0246. * indicates p < 0.05.
C and E) NPY inhibition of POMC neuronal firing activity in saline and in the presence of two different Y1 antagonists, BIBP3226 and BIBO0334 (indicated by the bars).
Note that 1 M of either BIBP3226 or BIBO0334 significantly suppressed the inhibitory effect of 25 and 40 nM NPY on the firing activity.
D and F) Averages (±sem) of normalized inhibitory effect of NPY on POMC neurons in saline and in the presence of 0.5 to 1.0 M BIBP3226 (n = 6) and 1.0 M
BIBO0334 (n = 9) * indicates p < 0.05, ** indicates p < 0.001.
G) Coapplication of both 1.0 M BIBP3226 and BIBO0336 significantly and completely blocked the inhibitory effect of 25 nM NPY on POMC neuronal activity.
H) Average (±SEM) inhibitory effects of 25–50 nM NPY on firing activity of six POMC cells in saline and in the presence of 1 M of both BIBP3226 and BIBO0334.
* indicates p < 0.05.tested (p < .05, n = 4, Figures S1A and S1B in the Supplemen-
tal Data available with this article onlline). Furthermore, applica-
tion of this peptide caused an average membrane hyperpolar-
ization of –10.3 ± 2.3 mV in 5 POMC cells tested (Figures S1ACELL METABOLISM : SEPTEMBER 2005and 4D). Thus, PYY3–36 application results in the hyperpolariza-
tion of POMC cells, resulting in a reduction in firing rate.
Although results obtained from experiments using blockers
of GABA , and ionotropic glutamate transmission suggest a195
A
S H O R T A R T I C L EFigure 4. PYY3–36 inhibits POMC neurons via activation of a K+ current on the postsynaptic cell
A) The effect of PYY3–36 on firing activity of an ARC POMC neuron in saline or in the presence of picrotoxin (100 M), NBQX (20 M), and AP5 (25 M) (indicated by
the bars) to block GABAA and ionotropic glutamate neurotransmission, respectively. These blockers failed to affect the inhibitory effect of 50 nM PYY3–36.
B) Inhibitory effect of PYY3–36 on 4 POMC neurons in saline or in the presence of blockers of GABAA and ionotropic glutamate transmission. n.s., not significant; p > 0.1.
C) In the presence of TTX, a blocker of the action potential-dependent synaptic transmission, 20 nM PYY3–36 elicited hyperpolarizations of membrane potentials.
D) The average (±SEM) of PYY3–36-induced hyperpolarizations of ARC POMC cells in control and in the absence of synaptic transmission in seven POMC neurons.
n.s. not significant; p > 0.1.
E) Steady-state current-voltage relationship from a POMC neuron (see Figure S2) in control and in the presence of the peptide.
F) Net current-voltage relationship for PYY3–36-induced conductance, of the same cell in (E), was obtained by subtracting the current value measured in the presence
of the peptide from that obtained in control at each potential.
G) Plot of mean (±SEM) net currents induced by PYY3–36 in 12 POMC neurons.direct postsynaptic action for PYY3–36 (Figures 4A and 4B),
these experiments did not rule out a role for any other neuro-
transmitter in the observed hyperpolarization of POMC neu-
rons. We therefore tested the actions of PYY3–36 after blockade
of activity-dependent neurotransmitter release using the Na+-
channel blocker tetrodotoxin (TTX). In POMC neurons pre-
treated with TTX, PYY3–36 generated membrane hyperpolariza-
tions in all 7 cells tested with an average of –12.0 ± 2.1 mV
(Figures 4C and 4D). Furthermore, the mean hyperpolarization
observed in the presence of TTX was not significantly different196(p > 0.5, unpaired t test) from that obtained in control (−10.3 ±
2.3, Figure 4D).
Ionic basis of current underlying the PYY3–36
induced hyperpolarization
We next investigated the nature of the current underlying the
generation of hyperpolarization caused by PYY3–36 in POMC
cells. To study the ionic basis of the current underlying the
PYY3–36-induced hyperpolarization, we compared the current-
voltage (I-V) relationships of the POMC cells obtained in the
absence or presence of PYY .CELL METABOLISM : SEPTEMBER 2005
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current responses of each cell to a voltage protocol that gener-
ated families of depolarizing and hyperpolarizing voltage steps
(250 ms long) applied from −55 mV. This protocol was repeated
at regular intervals in control, in the presence of 50 nM PYY3–36
and after 5–10 min of washout of the peptide.
Current and voltage traces from between 3 and 6 successive
trials in saline were then digitally averaged offline and were
compared with similarly averaged traces from an identical
number of trials obtained in the presence of PYY3–36, and wash
out (Figure S2). The steady-state values of the averaged cur-
rent responses elicited under each condition were then plotted
as a function of the corresponding voltage step to obtain indivi-
dual I-V relationships (Figure 4E). The net I-V relationship was
then constructed by subtracting the current values obtained in
PYY3–36 from those for the corresponding voltage in saline (Fig-
ure 4F). Net I-V relationships from 12 POMC cells were then
averaged, yielding the average (± sem) net I-V response in-
duced by PYY3–36 for these 12 POMC neurons (Figure 4G,
n = 12).
In these cells, PYY3–36 induces a reversible increase in con-
ductance with an equilibrium potential of around –90 mV and
is a net outward conductance positive to this potential. This
current presumably underlies the hyperpolarization of POMC
cells caused by PYY3–36 seen in current clamp recordings.
Since the estimated Nernst reversal potential of K+ ion in our
preparation is –100 mV, the current evoked by PYY3–36 applica-
tion is probably carried almost entirely by potassium ions
Discussion
PYY3–36 potently inhibits POMC neurons acting
at a postsynaptic Y2 receptor site
In this study, we show that PYY3–36 potently and reversibly in-
hibits firing activity of arcuate POMC neurons. In loose patch
recordings, in which the internal milieu of the neuron remains
undisturbed, 66 out of 68 POMC neurons responded to bath
application of more than 1 nM PYY3–36 with a significant de-
crease in firing activity. Application of a Y2-preferring agonist
[ahx5–24]NPY mimicked the inhibitory effects of PYY3–36, con-
sistent with the observation that PYY3–36 has a strong affinity
for Y2 receptors (e.g., [Keire et al., 2002]). Furthermore, the Y2
specific antagonist BIIE0246 completely blocked the inhibitory
actions of PYY3–36, while the Y1- and Y5-specific antagonists
did not. Thus, the data presented here demonstrate that the
inhibition of POMC neuronal firing by PYY3–36 is specifically
mediated by the Y2 receptor. Interestingly, the NPY–induced
inhibition of POMC neuronal activity reported previously (Rose-
berry et al., 2004) was only partially blocked by either the Y2
(BIIE0246) or Y1 (BIBP3226 or BIBO3304) receptor antagonists
(Figures 3A–3F). However, we show that coapplication of the
blockers almost completely abolished the inhibitory responses
of POMC cells to NPY, suggesting a role of both of these re-
ceptors in mediating the response to NPY.
The response of POMC neurons to PYY3–36 remained intact
when iontotropic glutamate and GABAA receptors were
blocked, indicating that the site of action of PYY3–36 is proba-
bly not presynaptic to POMC neurons. This hypothesis was
further supported by data obtained from whole cell recordings.
In current clamp recordings of TTX-pretreated POMC cells
where action potential-dependent transmitter release is blocked,CELL METABOLISM : SEPTEMBER 2005PYY3–36 induced a significant hyperpolarization comparable to
that observed in the absence of TTX also consistent with a
postsynaptic site of action for PYY3–36. Furthermore, the I-V
analysis of the response to PYY3–36 indicate that this peptide
reversibly increases the membrane conductance of POMC
cells. The averaged net current from 12 cells indicate that
PYY3–36 activates a voltage-independent conductance (w0.6nS)
which flows outwardly at membrane potentials near the action
potential threshold and reverses around –90 mV. Based on the
estimated reversal potential for K+ of –100 mV, the PYY3–36-
activated current is likely due to the increased flow of K+ ions
across the cell membrane.
Evidence for postsynaptic expression
of Y2 on ARC POMC cells
NPY, an agonist at most Y receptor subtypes, also potently
and reversibly inhibits POMC neurons (Roseberry et al., 2004).
Since Y1 and Y2 receptors both couple to Gi/o, the binding of
ligand to either postsynaptic receptor on POMC cells should
result in a similar action. While the inhibitory Y2 receptor is
most often found presynaptically on nerve terminals, postsyn-
aptic expression has been documented in cultured sensory
neurons (Bleakman et al., 1991) and certain suprachiasmatic
neurons (Obrietan and van den Pol, 1996). Interestingly, in a
recent study, Fetissov and colleagues (2004) studied Y2 and Y5
receptor distribution in knockout mouse strains in which the
receptor coding sequences were replaced with a functional
β-galactosidase coding sequence. While most of the β-galac-
tosidase-immunoreactive cells in the arcuate of the Y2R-
knockout mice coexpressed NPY, they also observed coex-
pression of β-endorphin and β-galactosidase in some cells,
suggesting that POMC neurons may also express Y2 receptors
(Fetissov et al., 2004).
Contribution of endogenous activity of Y1 receptor
to basal firing activity of POMC neurons
Our data indicate that bath application of the Y2 or Y5 selective
blocker failed to significantly alter the frequency of spontane-
ous action potential firing tested on 19 POMC cells (p > 0.1,
n = 19). Interestingly however, application of BIBP3226, the se-
lective blocker of Y1 receptor, significantly increased firing ac-
tivity of 12 other POMC neurons tested to 3.93 ± 0.81 Hz from.
2.46 ± 0.41 Hz in control (w38% increment, p < 0.01, n = 12,
data not shown), suggesting existence of an endogenous acti-
vation of Y1 receptor contributing to the basal neuronal activity.
However, this increase in firing activity could possibly be due
to a nonspecific effect of BIBP3226 on POMC neurons. This
hypothesis was further investigated by employing a structurally
different blocker of Y1 receptor, BIBO3304. Application of this
blocker on 9 POMC cells reproduced the increase of neuronal
firing activity (to 3.75 ± 0.98 Hz from 1.81 ± 0.69 Hz in control,
p < 0.05, n = 12, data not shown) observed by BIBP3226.
These observations suggest that in our preparation there exists
an endogenous activation of Y1, but not Y2 or Y5 receptors,
contributing to the basal action potential activity of POMC
neurons.
Mechanism of PYY3–36 induced inhibition of food intake
Preliminary reports describing the anorexigenic actions of
PYY3–36 suggested that this gut peptide might somehow ac-
cess arcuate nucleus neurons from the periphery and inhibit197
S H O R T A R T I C L Efood intake by indirectly stimulating anorexigenic POMC neu-
rons (Batterham et al., 2002). This hypothesis was supported
by observations that i.p. administration of PYY3–36 increased
expression of c-fos in POMC neurons (Batterham et al., 2002;
Halatchev et al., 2004), increased expression of POMC mRNA
(Challis et al., 2003), and increased the firing rate of POMC
neurons in hypothalamic slice preparations (Batterham et al.,
2002). Since the Y2 receptor was shown to be expressed as
an inhibitory autoreceptor on arcuate NPY cells (Broberger et
al., 1997), PYY3–36 was proposed to increase firing of POMC
neurons by activating inhibitory presynaptic Y2 receptors on
NPY/GABA/AgRP cells, thereby decreasing tonic inhibitory
GABA release onto these POMC cells (Batterham et al., 2002).
In that report, the effects of PYY3–36 in whole cell recordings
on action potential frequency were irreversible. Here, by con-
trast, in 66 out of 68 POMC neurons we demonstrate a potent,
readily reversible, concentration-dependent, inhibitory action
of PYY3–36. Furthermore, this effect did not depend on the
mode of electrophysiological recording. There are several po-
tential explanations for the discrepancy between the two
studies. The results reported in Batterham et al., a very small,
nonwashable, effect on membrane potential and firing rate in
whole cell mode, are consistent with a preparation in which
only the presynaptic actions of PYY3–36 on NPY cells are being
detected in the POMC neuron. If this were the case, PYY3–
36 would still decrease GABA release onto POMC cells, thus
producing the increase in firing rate. Such conditions could po-
tentially result from any number of factors, including differ-
ences in the age of the animals (4–6 weeks in Batterham et al.
versus 8–9 weeks in this study), the angle of the brain slice, or
inadvertent selection of a subgroup of POMC neurons based
on localization, or size of the cells. In this study, we attempted
to record from POMC cells across a wide range of their rostro-
caudal distribution, and saw no difference in their response as
a function of this parameter. A second potential explanation
is more technical in nature. The arcuate POMC neurons are
extremely small and unstable, and often fire periodically, thus
making them difficult to obtain stationary recordings from. In
this study, we took great care to hold neurons in loose patch
mode for an average of over 20 min in order to insure the sta-
tionary nature of the firing activity, prior to the application of
compounds.
Finally, the claim that PYY3–36 inhibits food intake by stimu-
lating POMC neurons is inconsistent with more recent observa-
tions that PYY3–36 retains its anorexigenic potential even in
POMC knockout (Challis et al., 2004), MC4-R knockout (Ha-
latchev et al., 2004), and obese agouti mice (Martin et al., 2004)
strains that all exhibit obesity syndromes due to defective
central melanocortin signaling (Robinson et al., 2000). Thus,
the present data demonstrate the existence of inhibitory Y2 re-
ceptors on the surface of arcuate POMC neurons, in addition
to the inhibitory Y1 receptors previously demonstrated (Rose-
berry et al., 2004). These data do not contradict the finding
that PYY3–36 acts on NPY neurons to decrease the release of
GABA onto POMC cells (Batterham et al., 2002). However, the
finding of inhibitory Y2 receptors on arcuate POMC neurons
adds an additional level of complexity to the regulation of the
arcuate NPY/POMC circuit, and suggests that the action of
either endogenous or exogenous Y2 ligands in the arcuate may
be very context dependent. For example, during starvation ar-
cuate NPY neurons are potently activated (Takahashi and198Cone, 2005), and the main signal from the arcuate as a whole
is orexigenic. Under these conditions, the action of Y2 ligands
on the arcuate may inhibit food intake, and indeed experiments
demonstrating inhibition of food intake by intraarcuate admin-
istration of Y2 agonists were performed under these conditions
(Batterham et al., 2002). In contrast, in a state in which the
NPY neurons are quiescent, it is possible that food intake could
be stimulated by arcuate application of a Y2 agonist.
Experimental procedures
Slice preparation
Young adult POMC-EGFP mice (Cowley et al., 2001) were deeply anaesthe-
tized with halothane prior to decapitation. The brain was entirely removed
and immediately submerged in ice-cold, gassed (95% O2, 5% CO2) aCSF,
containing (in mM): 133.2 NaCl, 3.1 KCl, 2 CaCl2, 1 MgCl2, 1 NaH2PO4,
26.2 NaHCO3, 10 glucose, 320 mosm/kg, pH 7.39 when gassed with 95%
O2, 5% CO2. A brain block containing hypothalamus was then made to cut
coronal slices of 200 um thickness using a vibrating slicer (VT1000S, Leica
Microsystems, Wetzlar, Germany). After slice preparation was complete, the
slices were incubated at 30°C for at least 1 hr before being transferred to
a recording chamber.
Electrophysiology
Slices were transferred to the recording chamber (w0.7 ml in volume) and
allowed to equilibrate for 10–20 min bathed with the oxygenated warm
(30°C–31°C) aCSF following 2–3 ml/min. During loose patch extracellular
recording, patch pipettes were filled with recording aCSF and had resist-
ances betweenw1.6–2.8 M and were used to form seals of between 4–11
M resistance (Rseal). Whole-cell recordings were performed using patch
pipettes of 2.2–5 M resistance when filled with a solution containing (in
mM); 125 K gluconate, 8 KCl, 5 MgCl2, 10 HEPES, 5 NaOH, 4 Na2ATP, 0.4
Na3GTP, 15.4 sucrose, and 7 KOH, which resulted in a pH w7.23 and os-
molality of 295–300 mosmol/kg.
Data analysis
Data, presented as mean ±SEM, were obtained from paired groups of con-
trol and treatment, except in the case of Figures 4C and 4F. The frequencies
of firing in control and treatment groups were compared by paired Student’s
t test. Percent of changes of firing in control and treatment groups were
compared by the nonparametric Wilcoxon signed rank test. The unpaired
data groups were compared by unpaired t test. Significance level was set
to 0.05 for all tests.
Supplemental data
Supplemental Data include two figures and Supplemental Experimental Pro-
cedures and can be found with this article online at http://www.cellmetabolism.
org/cgi/content/full/2/3/191/DC1/.
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